JC10 Rec'd PCT/PTO 09 MAY 2005 PCT

Application No. 10/521,040

Page dated May 5, 2005

Attorney Docket No. 0470-050079

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

: 10/521,040

Applicants

Herman Jan Tijmen Coelingh-Bennink et al.

Filed

: January 12, 2005

Title

PHARMACEUTICAL COMPOSITION COMPRISING

ESTETROL DERIVATIVES FOR USE IN CANCER

THERAPY

Group Art Unit

Not yet assigned.

Examiner

Not yet assigned.

Customer No.

28289

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the requirements of 37 CFR §§ 1.56, 1.97, and 1.98, the Applicants hereby submit this Information Disclosure Statement together with a completed Form PTO/SB/08A and one copy of the references, other than the United States patents, listed thereon.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 5, 2005.

Helen Gerace

(Name of Person Mailing Paper)

nature

Date

Application No. 10/521,040 Paper dated May 5, 2005 Attorney Docket No. 0470-050079

This application is the United States national phase of PCT Application No. PCT/NL2003/000513. The International Search Report dated October 7, 2003, for the underlying PCT Application, identified the references listed on Form PTO/SB/08A. A copy of the International Search Report also is enclosed for the Examiner's convenience.

Pursuant to 37 C.F.R. § 1.97(b) 3, no fee is believed to be due for the submission of this Information Disclosure Statement, as it is being submitted before the mailing date of a first Office Action on the merits. Nevertheless, the Commissioner for Patents is hereby authorized to charge any fees which may be required to Deposit Account No. 23-0650. One (1) original and two (2) copies of this Information Disclosure Statement are enclosed.

Respectfully submitted,

THE WEBB LAW FIRM

William H. Løgsdøn

Registration No. 22,132 **Attorney for Applicants**

700 Koppers Building

436 Seventh Avenue

Pittsburgh, PA 15219-1818

Telephone: 412-471-8815

Facsimile: 412-471-4094

E-mail: webblaw@webblaw.com

Approved for use through 10/31

PTO/SB/08A (08-00) OMB 0651-0031

U.S. Patent and Trademark Office: U.S. PEPARTMENT OF COMMERCE perwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete	e if Known
Application Number	10/521,040
Filing Date	January 12, 2005
First Named Inventor	Herman Jan Tijmen Coelingh-Bennink et al.
Group Art Unit	Not yet assigned.
Examiner Name	Not yet assigned.
Attorney Docket Number	0470-050079

U.S. PATENT DO	CUMENTS
----------------	---------

			J	.S. I AILNI DOGG	MILITIO	
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant
		Number	Kind Code ²		MM-DD-YYYY	Passages or Relevant Figures Appear
,		5,340,585	Α	Pike, Malcolm C. et al.	08/23/1994	
		5,340,584	A	Spicer, Darcy V.	08/23/1994	
		4,937,238	- -	Lemon, Henry M.	06/26/1990	
	-	5,468,736	Α	Hodgen, Gary D.	11/21/1995	,
·						
,	ļ					
	1	t .		1	1	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite	Foreign Patent Do	cument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	No.	Office ³ Number ⁴	Kind - Code ⁵				
		WO 94/26207		University of Southern California	11/24/1994		
·		WO 02/100877	A1	Southwest Foundation for Biomedical Research	12/19/2002		
		WO 02/094276	A1	Pantarhei Bioscience B.V.	11/28/2002		
		-	· · · · · · · · · · · · · · · · · · ·				
			-				
	<u> </u>					V 8 90 70 8 70 A	
	<u>Ļ</u>						
Examiner Signature					Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria VA 22313-1450

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.